By Counterforce Health Team in Waylivra (volanesorsen) —

How to Get Waylivra (Volanesorsen) Covered by Aetna CVS Health in New Jersey: Appeals Guide and Policy Details

Answer Box: Getting Waylivra Covered by Aetna CVS Health in New Jersey

Waylivra (volanesorsen) is not on Aetna's standard formulary and requires a medical exception appeal, not routine prior authorization. For familial chylomicronemia syndrome (FCS), you'll need genetic confirmation, triglycerides >875 mg/dL on multiple tests, documented failure of conventional therapies, and a specialist's medical necessity letter. Submit through Aetna's provider portal or fax. If denied, New Jersey's Independent Health Care Appeals Program (IHCAP) offers binding external review within 180 days.

First step today: Contact your lipid specialist to begin compiling genetic testing, lab results, and prior treatment documentation.

Table of Contents

  1. Understanding Aetna CVS Health Plan Types in New Jersey
  2. Waylivra's Formulary Status and Coverage Pathway
  3. Medical Exception Requirements and Documentation
  4. Specialty Pharmacy Process Through CVS
  5. Submission Process and Forms
  6. Appeals Process: Internal and External Review
  7. Common Approval Patterns and Success Strategies
  8. Cost Considerations and Financial Assistance
  9. When to Escalate to New Jersey Regulators
  10. FAQ: Waylivra Coverage Questions

Understanding Aetna CVS Health Plan Types in New Jersey

Your specific Aetna plan type affects how Waylivra coverage requests are processed in New Jersey. Here's what you need to know:

HMO Plans: Require referrals to specialists and typically have stricter prior authorization requirements. Your primary care physician must refer you to a lipid specialist before Waylivra can be considered.

PPO Plans: Allow direct access to specialists but may have higher cost-sharing for out-of-network providers. Most Waylivra requests will need to go through in-network lipidologists.

EPO Plans: Combine features of both but generally don't cover out-of-network care except in emergencies.

Medicaid Plans (Aetna Better Health): Follow New Jersey Medicaid guidelines and may have additional state-specific requirements for rare disease medications.

Note: All Aetna plan types in New Jersey must comply with state insurance regulations, including the right to external review through IHCAP after internal appeals are exhausted.

Waylivra's Formulary Status and Coverage Pathway

Waylivra (volanesorsen) does not appear on Aetna CVS Health's 2024 or 2025 specialty drug formulary lists, making it a non-formulary medication that requires special consideration.

Coverage at a Glance

Requirement Details Where to Find It
PA Required Medical exception appeal (not standard PA) Aetna Specialty Drug List
Formulary Tier Non-formulary Same source
Step Therapy Must document failure of FDA-approved alternatives Aetna clinical policies
Specialty Pharmacy CVS Specialty required if approved CVS Specialty Drug List
FDA Status Not approved in US (EU approval only) FDA Orange Book

Alternative Medications: Since Waylivra isn't FDA-approved, Aetna will likely require documentation of why FDA-approved alternatives like Tryngolza (olezarsen) aren't appropriate for your specific case.

Medical Exception Requirements and Documentation

Getting Waylivra covered requires proving medical necessity through comprehensive documentation. Here's what you need:

Essential Clinical Documentation

Confirmed FCS Diagnosis:

  • Genetic testing showing biallelic pathogenic mutations in LPL, APOC2, APOA5, LMF1, or GPIHBP1 genes
  • Clinical FCS score ≥45 (if genetic testing unavailable)
  • ICD-10 code: E78.3 (Hyperchylomicronemia)

Laboratory Evidence:

  • Minimum three fasting triglyceride levels >875 mg/dL, taken at least one month apart
  • Exclusion of secondary causes (diabetes, hypothyroidism, kidney disease)
  • Recent lipid panel showing persistent severe hypertriglyceridemia

Treatment History:

  • Documented trial and failure/intolerance of:
    • Fibrates (fenofibrate, gemfibrozil)
    • High-dose omega-3 fatty acids
    • Dietary modifications (very low-fat diet)
    • Statins (if applicable)

Clinical Complications:

  • History of acute pancreatitis episodes
  • Hospitalization records related to hypertriglyceridemia
  • Impact on quality of life documentation

Specialist Requirements

Your medical necessity letter must come from a board-certified:

  • Endocrinologist with lipid subspecialty
  • Lipidologist
  • Geneticist (for rare metabolic disorders)

The letter should reference European treatment guidelines and published clinical evidence supporting Waylivra's use in FCS.

Specialty Pharmacy Process Through CVS

If Waylivra is approved, it must be dispensed through CVS Specialty Pharmacy as Aetna's preferred specialty partner.

Patient Enrollment Steps

  1. Prescription Routing: Your doctor sends the prescription directly to CVS Specialty
  2. Patient Intake: CVS Specialty calls to verify insurance and collect clinical information
  3. Prior Authorization: CVS Specialty coordinates with Aetna for coverage determination
  4. Shipping Setup: Medication is shipped directly to your home with cold-chain handling

CVS Specialty Contact: 1-800-237-2767

Important: Since Waylivra isn't FDA-approved, special importation arrangements may be required even if coverage is approved.

Submission Process and Forms

Step-by-Step Submission Process

Step 1: Gather Documentation (Patient/Clinic)

  • Complete medical records
  • Lab results and genetic testing
  • Prior treatment documentation
  • Insurance information

Step 2: Complete Medical Exception Request (Prescriber)

  • Use Aetna's medical exception form
  • Submit via provider portal or fax: (verify current number with Aetna)
  • Include comprehensive medical necessity letter

Step 3: Follow Up (Clinic Staff)

  • Track submission status
  • Respond to requests for additional information within 2 business days
  • Monitor for determination letter

Timeline: Standard review takes 30-45 days; expedited review (if urgent) within 72 hours.

Required Forms and Portals

  • Electronic Submission: CoverMyMeds platform
  • Provider Portal: Aetna provider website
  • Fax Submission: Contact Aetna for current specialty medication fax numbers

Appeals Process: Internal and External Review

Aetna Internal Appeals

Level 1 Internal Appeal:

  • Deadline: 180 days from denial
  • Timeline: 30-45 days for decision (72 hours if expedited)
  • Submission: Written appeal with additional clinical evidence

Level 2 Internal Appeal (if available):

  • Deadline: 60 days from Level 1 denial
  • Timeline: 30 days for decision

New Jersey External Review (IHCAP)

After exhausting internal appeals, New Jersey residents can request external review through the Independent Health Care Appeals Program.

Key Details:

  • Administrator: Maximus Federal Services
  • Deadline: 180 days from final internal denial
  • Cost: Free to patient (insurer pays)
  • Timeline: 45 days for decision (expedited available)
  • Contact: 1-888-393-1062

Required Documents:

  • Final denial letter from Aetna
  • Complete medical records
  • Treating physician's letter of support
  • IHCAP application form
Legal Authority: Under N.J.S.A. 26:2S-11, external review decisions are binding on insurers.

Common Approval Patterns and Success Strategies

Based on similar rare disease medication appeals, successful Waylivra requests typically include:

Strongest Documentation Elements

Clinical Evidence:

  • Multiple triglyceride readings >1,000 mg/dL
  • Documented pancreatitis episodes requiring hospitalization
  • Genetic testing confirming biallelic FCS mutations
  • Detailed failure documentation of all conventional therapies

Specialist Support:

  • Letter from recognized lipid disorder center
  • References to European clinical guidelines
  • Explanation of why FDA-approved alternatives aren't suitable
  • Monitoring and safety plan

Administrative Completeness:

  • All forms completed in full
  • Timely responses to requests for additional information
  • Clear documentation of New Jersey residency and plan coverage

Cost Considerations and Financial Assistance

Insurance Coverage

  • If approved: Specialty tier copay/coinsurance applies
  • If denied: Full cost responsibility unless appealed successfully

Manufacturer Support

Since Waylivra is manufactured by Ionis/Akcea, check their patient assistance programs:

  • Income-based copay assistance
  • Free drug programs for qualifying patients
  • Bridge programs during appeals

State and Federal Programs

  • New Jersey Pharmaceutical Assistance to the Aged and Disabled (PAAD)
  • Patient Advocate Foundation copay relief programs
  • National Organization for Rare Disorders (NORD) assistance

When to Escalate to New Jersey Regulators

Contact New Jersey regulators if:

  • Aetna fails to meet appeal deadlines
  • You believe the denial violates state insurance laws
  • IHCAP process isn't followed properly

New Jersey Department of Banking and Insurance:

FAQ: Waylivra Coverage Questions

Q: How long does Aetna's review take for Waylivra? A: Standard medical exception reviews take 30-45 days. Expedited reviews (if medically urgent) are completed within 72 hours.

Q: Can I get Waylivra covered if I live in New Jersey but work in another state? A: Coverage depends on where your insurance plan is regulated. New Jersey residents with NJ-regulated plans can use IHCAP for external review.

Q: What if my triglycerides are below 875 mg/dL? A: Aetna typically requires triglycerides >875 mg/dL for FCS treatment consideration. Lower levels may require additional clinical justification.

Q: Does step therapy apply if I failed treatments in another state? A: Yes, documented treatment failures from other states are valid for New Jersey appeals, provided medical records are complete.

Q: Can I request a peer-to-peer review? A: Yes, your specialist can request to speak directly with Aetna's medical director to discuss the case before formal denial.

Q: What happens if IHCAP overturns Aetna's denial? A: Aetna must comply with IHCAP's decision and provide coverage. The decision is legally binding under New Jersey law.

Counterforce Health: Expert Appeals Support

Counterforce Health specializes in turning insurance denials into successful appeals for complex medications like Waylivra. Our platform analyzes denial letters, identifies specific appeal strategies, and helps clinicians draft evidence-backed medical necessity letters that address payers' exact requirements. For patients navigating Aetna's medical exception process, we provide the clinical documentation framework and procedural guidance that can make the difference between denial and approval.

From Our Advocates: We've seen Waylivra appeals succeed when the specialist clearly explains why FDA-approved alternatives like olezarsen aren't clinically appropriate for the specific patient. The key is documenting unique clinical factors—whether genetic variants, prior treatment responses, or comorbidities—that make Waylivra the medically necessary choice. This personalized clinical rationale, combined with complete FCS documentation, significantly strengthens the appeal.

Sources & Further Reading

Disclaimer: This guide provides educational information about insurance coverage processes and should not be considered medical or legal advice. Coverage decisions vary by individual circumstances and plan details. Always consult with your healthcare provider and insurance plan directly for personalized guidance. For assistance with appeals and coverage questions, contact New Jersey's Department of Banking and Insurance at 1-800-446-7467.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.